QIAstat-Dx
assay menu

  • Prepare your lab for a high volume of respiratory tests with a streamlined multiplex test. With a single-step solution, your lab will easily adapt to increased demand this flu season could bring. The QIAstat-Dx panels redefines ease-of-use with less than one-minute hands-on time and a seamless sample to result workflow.

    With the QIAstat-Dx Panels:

    • Save time – all reagents are preloaded into the cartridge
    • Reduce errors – tests are performed on a single instrument solution
    • Lower costs – cartridges are shipped and stored at room temperature

  • QIAstat-Dx Respiratory Panel

    True Sample to Insight solution for patients with suspected upper respiratory infections. Detects 20 viral and bacterial targets in about an hour.

    Download the flyer

    Get product information

  • QIAstat-Dx Respiratory SARS-CoV-2 Panel

    (Emergency Use Authorization)

    This expanded version of our multiplex respiratory cartridge detects and differentiates* 21 viral and bacterial respiratory targets, including SARS-CoV-2 to support efforts to provide accessible testing to meet the demands of the COVID-19 outbreak.

    Download the flyer

    Get product information and resources

    *Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Be the first to know about QIAstat-Dx news and webinars

Send me updates
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
  • This test has not been FDA cleared or approved;
  • This test has been authorized by FDA under an EUA for use by authorized laboratories;
  • This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
  • Social Sharing